Regeneron Pharmaceuticals, Inc.; Inc.;Institute for Research in Biomedicine (IRB);Yale University;Regeneron Pharmaceuticals
发明人:
STEVENS, Sean,MURPHY, Andrew J.,FLAVELL, Richard,EYNON, Elizabeth,GALAN, Jorge,WILLINGER, Tim,MANZ, Markus,RONGVAUX, Anthony,YANCOPOULOS, George D.
申请号：
AU2015255177
公开号：
AU2015255177B2
申请日:
2015.11.10
申请国别(地区):
AU
年份:
2017
代理人:
摘要：
#$%^&*AU2015255177B220170608.pdf#####ABSTRACT A mouse with a humanization of the mlL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mll2rg subunit gene； and optionally a humanization of the TPO gene is described. A RAG/ll2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., S. typhi or M. tuberculosis is described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g. a myeloid leukemia or a myeloproliferative neoplasia.
